Edgen Stock·Dec 13 2025, 16:02Back
Immunovant Shifts Focus With $550M For Autoimmune Drug
Edgen Stock·Dec 13 2025, 16:02
[1] Edesa Biotech Reports Fiscal Year 2025 Results - The Manila Times (https://www.manilatimes.net/2025/12/13/tmt-ne ...)[2] Arcus halts Gilead-partnered TIGIT trials as biotech reworks R&D focus - Fierce Biotech (https://www.fiercebiotech.com/biotech/arcus-h ...)[3] Amgen Scores Uplizna Expansion Into Generalized Myasthenia Gravis - BioSpace (https://www.biospace.com/fda/amgen-scores-upl ...)
